European Union announces new programme to improve Parkinson’s diagnosis

News

Author: Parkinson's Life editorsPublished: 17 January 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

PD-Podcast-DBS

The European Union has announced the launch of the Magnetic Diagnostic Assay for Neurodegenerative Diseases (MADIA) – a project with the ultimate goal of improving diagnosis for those living with Parkinson’s and Alzheimer’s.

The project, which is in partnership with a range of international universities and institutions, will focus on the development of a novel device that will help clinicians perform a simple click and analysis to diagnose both conditions.

Dr Francisco Campos, of the Clinical Neurosciences Research Laboratory, said: “An early diagnosis is crucial to maximise the effectiveness of the treatments in order to mitigate the devastating effects of these illnesses and slow disease progression.

“MADIA is funded by the European Union’s Horizon 2020 research and innovation programme, and consists of a multitasking team with more than 50 professionals in the fields of biology, physics and engineering.”

For comprehensive information about Parkinson’s diagnosis please visit the EPDA website.

Go Back

Share this story

Comments


Related articles


Consultative neurology

In my country

Telemedicine: how Sweden is reducing waiting times for Parkinson’s treatment

Video calling tech is speeding up access to advanced treatment

READ MORE
My-Angel-My-Hero

Global update

Online video campaign ‘gives life’ to powerful Parkinson’s stories

Campaign calling for inspiring video testimonials from patients

READ MORE
My PD Journey

Europe

A better way to assess the impact of Parkinson’s

EPDA experts launch pilot 'quality of life' study

READ MORE